Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 26 January 2017 | By Michael Mezher
France's Agency Nationale de Sécurité du Médicament et des Produits de Santé (ANSM) on Wednesday reported positive results for its year-long pilot for assessing clinical trials using the process established in the new EU Clinical Trials Regulation.
In 2014, Regulation (EU) No. 536/2014, known as the new Clinical Trials Regulation, was adopted. The goal of the regulation is to provide faster, more coordinated assessments for clinical trial applications through a central portal. The regulation also promises to improve transparency through the publication of clinical trials via a public database.
While the Clinical Trials Regulation was initially expected to take effect in May 2016, the regulation is effectively delayed until the EU clinical trials portal and database are completed.
In preparation for the Clinical Trials Regulation coming into effect, ANSM launched a voluntary pilot in September 2015 to simulate clinical trial application reviews under the new regulation.
In the pilot, which involved both academic and industrial clinical trials sponsors, ANSM sought to provide sponsors with a decision from the agency and corresponding ethics committee for clinical trials applications within 60 days.
According to ANSM, the pilot represented "positive progress for all concerned."
During the one year, ANSM says it received a total of 897 clinical trials applications. Of these, 112 (12.5%) were assessed as part of the pilot. ANSM also notes that the amount of clinical trials submitted to the pilot increased in the second half, with 51 submissions in the first six months and 61 submissions in the second six months.
By the end of the pilot's first year, ANSM says it completed assessments for 89 of the 112 submissions it received. Of these, ANSM authorized 73 trials and rejected applications for 16, with an average time to notification of 64.3 days.
While this figure is slightly longer than the 60 days specified in the Clinical Trials Regulation, ANSM says that overall it was able to meet the time frames for each stage of the assessment process, and that "in the majority of cases one decision was returned within the deadline imposed by the current legislation."
ANSM
Updated Guide
Tags: ANSM, Clinical Trials Regulation
Regulatory Focus newsletters
All the biggest regulatory news and happenings.